Business
IXICO to Present AI Segmentation Research
IXICO to Present AI Segmentation Research.
About this update from Ixico Plc
[{"type":"text","content":"\n \nRNS Number : 3606D IXICO plc 19 February 2020 \n\n \n19 February 2020\nIXICO plc\n(\"IXICO\" or the \"Company\")\n \nIXICO to Present AI Segmentation Research at Huntington's Disease Therapeutics Conference\nIXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, today announces that it is scheduled to present a scientific poster on enhancing imaging analysis accuracy for Huntington's Disease (HD) by comparing two types of Artificial Intelligence (AI) techniques at the CHDI Foundation 15th Annual 2020 Huntington's Disease Therapeutics Conference held from 24 - 27 February, 2020 in Palm Springs, California, USA. \nFurther details of the presentation are as follows:\nTitle: Fully automatic AI segmentation of subcortical regions: comparison of ATLAS and deep-learning based approaches\n \nWednesday, 26th February, Group B: Human Studies at 2.30 - 4pm, Poster number 101\nAuthors: Kirsi M Kinnunen1*, Jack Weatheritt1, Richard Joules1, Robin Wolz1,2\n \nChanges in the volume of the caudate and putamen regions are used as biomarkers to track the development of Huntington's disease and monitor the potential effect of interventional treatments. Accurate volume calculations, obtained via segmentations, are therefore of utmost clinical importance. This poster compares and contrasts two AI approaches for anatomical segmentation - the first is an established atlas-based manifold learning technique, IXICO's proprietary LEAP technology; the second is a deep-learning model based on a 3D convolutional neural network (CNN). \nDr Robin Wolz, Senior Vice President, Science & Innovation at IXICO commented: \"Huntington's Disease continues to be a focus for IXICO in its efforts to provide pioneering technologies to support the advancement of effective treatments for rare neurological diseases. Our research in imagi...